Effects of Vitamin D3 on asymmetric- and symmetric dimethylarginine in arterial hypertension.
Grübler MRDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria; Swiss Cardiovascular Center Bern, Department of Cardiology, Bern University Hospital, University of Bern, 3007 Bern, Switzerland. Electronic address: martin.gruebler@gmx.net.
Gaksch MDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
Kienreich KDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
Verheyen NDDepartment of Cardiology, Medical University of Graz, Graz, Austria.
Schmid JDepartment of Cardiology, Medical University of Graz, Graz, Austria.
Müllner CDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
Richtig GInstitute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.
Scharnagl HClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Trummer CDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
Schwetz VDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
Meinitzer AClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Pieske BDepartment of Cardiology, Campus Virchow, Charité University, Berlin, Germany.
März WClinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria; Synlab Academy, Synlab Services GmbH, Mannheim, Germany.
Tomaschitz ADepartment of Cardiology, Medical University of Graz, Graz, Austria; Bad Gleichenberg Clinic, Bad Gleichenberg, Austria.
Pilz SDepartment of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria; Department of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, VU University Medical Centre, Amsterdam, The Netherlands.
English
BACKGROUND AND AIMS Accumulating evidence has proposed a correlation between vitamin D (25(OH)D) insufficiency and cardiovascular (CV) disease. Vitamin D associated effects on endothelial function have been suggested to be a possible culprit. The present study investigated the association of vitamin D3 treatment on markers of endothelial dysfunction in patients with arterial hypertension.
METHODS AND RESULTS The Styrian Vitamin D Hypertension Trial is a double-blind, placebo-controlled, single-centre study conducted at the Medical University of Graz, Austria. A total of 200 study participants with arterial hypertension and 25(OH)D levels below 30ng/mL were enrolled. The study participants were randomized to receive 2800 IU of vitamin D3 per day as oily drops (n=100) or placebo (n=100) for a duration of eight weeks. The present study uses an analysis of covariance (ANCOVA) to investigate the effect of vitamin D3 treatment on symmetric (SDMA) and asymmetric dimethylarginine (ADMA). A total of 187 participants (mean [SD] age 60.0 [11.3] years; 47% women; 25(OH)D 21.2 [5.6]ng/mL; mean systolic blood pressure of 131.4 [8.9] mmHg on a median of 2 antihypertensive drugs) completed the trial. Mean treatment effect was -0.004 (95%CI [-0.03 to 0.04]; P=0.819) on ADMA and 0.001 (95%CI [-0.05 to 0.05]; P=0.850) on SDMA. In the subgroup analysis patients with a 25(OH)D concentration <20ng/mL had a significant increase in their log l-arginine/ADMA ratio (mean treatment effect 18.4 95%CI [1.84-34.9]μmol/L/μmol/L; P=0.030). ClinicalTrials.gov Identifier: NCT02136771 EudraCT number: 2009-018125-70 CONCLUSIONS: Vitamin D3 supplementation in hypertensive patients with low 25-hydroxyvitamin D has no significant effect on ADMA and SDMA.